U2Bio Co., Ltd. (KOSDAQ:221800)
26,850
+900 (3.47%)
At close: Feb 26, 2026
U2Bio Revenue
U2Bio had revenue of 6.87B KRW in the quarter ending September 30, 2025, with 6.81% growth. This brings the company's revenue in the last twelve months to 25.59B, down -2.62% year-over-year. In the year 2024, U2Bio had annual revenue of 25.04B, down -18.68%.
Revenue (ttm)
25.59B
Revenue Growth
-2.62%
P/S Ratio
16.72
Revenue / Employee
n/a
Employees
n/a
Market Cap
427.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.04B | -5.75B | -18.68% |
| Dec 31, 2023 | 30.79B | -38.22B | -55.38% |
| Dec 31, 2022 | 69.01B | 58.01B | 527.29% |
| Dec 31, 2014 | 11.00B | 1.59B | 16.90% |
| Dec 31, 2013 | 9.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nepes | 503.41B |
| Devsisters corporation | 286.10B |
| C&C International | 271.51B |
| DIT Corp. | 130.36B |
| NC Chem | 119.15B |
| Humedix | 110.99B |
| KOSES Co.,Ltd | 78.34B |
| POONGWON PRECISION CO.,Ltd. | 31.17B |